Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Emma H Wilson · UNIVERSITY OF CALIFORNIA RIVERSIDE · 2022 · $8,000 — PROJECT SUMMARY: The organizers of the 16th International Congress on Toxoplasmosis and Toxoplasma gondii Research request support for this meeting, which will occur in May 2022, after a 1 year pandemic-re- lated delay. Toxoplasma gondii is a ubiquitous, protozoan parasite that is transmitted throug…
Umesh C Sharma · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2022 · $279,125 — Immunomodulation of Galectin-3 to Prevent Radiation-Induced Myocardial Fibrogenesis This application addresses the scientific goals of FOA-PA-19-112. More than half of life-threatening thoracic cancers are treated with repeated doses of ionizing radiation. Unfortunately, the pro-inflammatory and pr…
Kristina M. Adams Waldorf · UNIVERSITY OF WASHINGTON · 2021 · $864,027 — Project Summary Pregnant women are highly vulnerable to influenza A virus (IAV) and are at increased risk for maternal death, preterm birth and stillbirth. Universal influenza vaccines (UFV) are thought to be possible if conserved regions of influenza virus are targeted and appropriate immune respon…
Umesh C Sharma · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2021 · $279,125 — Immunomodulation of Galectin-3 to Prevent Radiation-Induced Myocardial Fibrogenesis This application addresses the scientific goals of FOA-PA-19-112. More than half of life-threatening thoracic cancers are treated with repeated doses of ionizing radiation. Unfortunately, the pro-inflammatory and pr…
Joseph Scaduto · CMTX BIOTECH, INC. · 2021 · $315,000 — PROJECT SUMMARY/ABSTRACT CMTx Biotech is a drug development company working to rescue and repurpose a proprietary clinical-stage drug candidate, incyclinide (CMT-3 / COL-3), for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and suffering from Co…
George A. Belov · UNIV OF MARYLAND, COLLEGE PARK · 2021 · $228,233 — Multiple enteroviruses are associated with life-threatening and economically important diseases, yet the licensed vaccines are only available against poliovirus and enterovirus 71. The antigenic diversity of enterovirus capsids restricts the protective efficacy of vaccines only to antigenically very…
Saraswati Pokharel · ROSWELL PARK CANCER INSTITUTE CORP · 2021 · $209,275 — Early Detection and Immunomodulation of PD-1 Inhibitor-Induced Cardiotoxicity Abstract The recent discovery of immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 blockers, has revolutionized the management of advanced stage malignancies including lung cancers, melanoma, head and neck, and…
William T Jackson · UNIVERSITY OF MARYLAND BALTIMORE · 2021 · $386,250 — Enteroviruses are among the most severe causes of human disease, and recent outbreaks of emerging enteroviruses such as types D68 and 71 have highlighted the need to understand more about these pathogens. Our comparative studies of poliovirus (PV), coxsackievirus B3, and now EV-D68 have shown many c…
William T Jackson · UNIVERSITY OF MARYLAND BALTIMORE · 2020 · $386,250 — Enteroviruses are among the most severe causes of human disease, and recent outbreaks of emerging enteroviruses such as types D68 and 71 have highlighted the need to understand more about these pathogens. Our comparative studies of poliovirus (PV), coxsackievirus B3, and now EV-D68 have shown many c…
REX L CHISHOLM · NORTHWESTERN UNIVERSITY AT CHICAGO · 2020 · $384,018 — PROJECT SUMMARY Since early 2020, COVID-19 disease spread rapidly across the US and will likely be sustained or recur periodically until an effective vaccine or prophylactic treatment is developed. The pandemic will have a large impact on the conduct of the next phase of eMERGE, including recruitmen…
George A. Belov · UNIV OF MARYLAND, COLLEGE PARK · 2020 · $189,608 — Multiple enteroviruses are associated with life-threatening and economically important diseases, yet the licensed vaccines are only available against poliovirus and enterovirus 71. The antigenic diversity of enterovirus capsids restricts the protective efficacy of vaccines only to antigenically very…
Saraswati Pokharel · ROSWELL PARK CANCER INSTITUTE CORP · 2020 · $258,790 — Early Detection and Immunomodulation of PD-1 Inhibitor-Induced Cardiotoxicity Abstract The recent discovery of immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 blockers, has revolutionized the management of advanced stage malignancies including lung cancers, melanoma, head and neck, and…
William T Jackson · UNIVERSITY OF MARYLAND BALTIMORE · 2019 · $386,250 — Enteroviruses are among the most severe causes of human disease, and recent outbreaks of emerging enteroviruses such as types D68 and 71 have highlighted the need to understand more about these pathogens. Our comparative studies of poliovirus (PV), coxsackievirus B3, and now EV-D68 have shown many c…
Hideki Aihara · UNIVERSITY OF MINNESOTA · 2022 · $619,646 — Abstract Viruses are a major threat to human health. Our laboratory uses various structural biology techniques to dissect molecular mechanisms of how viruses replicate and invade the host cell or its genome. One area of our major interest is retroviral integration, a critical step in the lifecycle o…
ELAN Z EISENMESSER · UNIVERSITY OF COLORADO DENVER · 2022 · $194,375 — PROJECT SUMMARY Coronaviruses (CoVs) have emerged as formidable human pathogens since their detection within human populations only 50 years ago, underlying the need to rapidly characterize their molecular mechanisms in order to thwart their infections through therapeutics. Seven CoVs that infect h…
Matthew Bogyo · STANFORD UNIVERSITY · 2022 · $196,750 — Project Summary Current strategies to overcome virus outbreaks are focused on development of effective vaccines as well as novel treatments that can either block infection or prevent mortality from the resulting disease. One of the strategies that has shown promise is the use of serum from patients …
Nitesh K Kunda · ST. JOHN'S UNIVERSITY · 2022 · $164,000 — Summary Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) is a highly infectious virus known to cause the 2019 coronavirus disease (COVID-19). The disease has been declared as a global pandemic by the World Health Organization. In the United States, as of January 20, 2021, we have more th…
Veronica Villanueva · RUSH UNIVERSITY MEDICAL CENTER · 2022 · $46,752 — Lupus nephritis (LN) and coronavirus disease 2019 (COVID-19) both display myeloid cell dysfunction which can lead to altered signaling resulting in tissue damage, such as kidney injury. Up to 50% of LN patients develop chronic kidney disease (CKD) and 25% of COVID-19 patients are reported to experie…
MICHAEL G ROSENFELD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2022 · $416,540 — ABSTRACT Alzheimer’s disease (AD) presents a formidable therapeutic challenge, as current interventions have failed to slow disease progression. The majority of AD genetic risk variants identified by GWAS reside in non- coding regions of the genome, suggesting that alterations in gene expression con…
Rebecca Michelle DuBois · UNIVERSITY OF CALIFORNIA SANTA CRUZ · 2022 · $379,529 — PROJECT SUMMARY Human astroviruses (HAstV) are a leading cause of viral diarrhea in children. Divergent HAstV strains are associated with fatal human encephalitis. Currently, no vaccines or antiviral therapies exist for HAstV infections. Our goal is to identify sites of vulnerability (Achilles' heel…